yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
Red Hat
The Opening of Virtualization
User Environment Management – The Third Layer of the Desktop
Cloud Computing for Business Agility
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Return on Assests: Bringing Visibility to your SOA Strategy
Managing Hybrid Endpoint Environments
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
How Can AJAX Improve Homeland Security?
Beyond Widgets: What a RIA Platform Should Offer
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
Today's Top SOA Links

Urologic Surgery Pioneer Dr. Alexander Gershman Joins Medistem's Scientific Advisory Board
Endometrial Stem Cell Company Expands Clinical Applications of Its Universal Donor Stem Cell Product

SAN DIEGO, CA -- (Marketwire) -- 11/19/12 -- Medistem (PINKSHEETS: MEDS) announced today appointment of Alexander Gershman, MD, Ph.D to the company's Scientific Advisory Board. Dr. Gershman is an internationally-renowned opinion leader in urological surgery having pioneered numerous minimally invasive procedures using laparoscopic techniques.

"The future of regenerative medicine lies not only in having the best stem cell product, but also being able to practically deliver it in a manner that can be integrated into existing medical practice," said Dr. Alan Lewis, CEO of Medistem. "Through working with respected physicians such as Dr. Gershman, our aim is to develop novel delivery methods so that our cellular product can be utilized in numerous disciplines."

Medistem is currently running a Phase II clinical trial in heart failure patients using its Endometrial Regenerative Cell (ERC) product delivered through a 30-minute minimally invasive patent pending procedure. The company seeks to develop similar minimally invasive procedures for the field of urology in collaboration with Dr. Gershman.

"It is obvious that stem cell medicine is the future of medicine. Although great strides have occurred in clinical entry of stem cells, a major hurdle to commercialization is practical implementation," said Dr. Gershman. "I commend Medistem for having discovered what appears to be the most potent blood vessel generating stem cell, the ERC, as well as having the foresight to think practically about optimum methods of delivery."

Dr. Gershman is one of the first surgeons in the world to apply the method of laparoscopic surgery and robotic-assisted surgery to urology. He currently holds numerous hospital appointments, including the following: Director of Institute of Advanced Urology at the Cedars-Sinai Medical Center; Director of Urologic Laparoscopy in the Division of Urology, Harbor-UCLA Medical Center; Head of Endourology Division, Department of Surgery, VA Greater Los Angeles Healthcare System; Attending Surgeon, Laparoscopic Renal Transplant Surgery, St. Mary Medical Center; Attending Surgeon at the Cedars-Sinai Medical Center; and Attending Surgeon at the Harbor-UCLA Medical Center.

About Medistem
Medistem Inc. is focused on the development of the Endometrial Regenerative Cell (ERC), a universal donor adult stem cell product. ERCs possess specialized abilities to stimulate new blood vessel growth and can differentiate into lung, liver, heart, brain, bone, cartilage, fat and pancreatic tissue. These unique properties have applications for treatment of critical limb ischemia (CLI), congestive heart failure (CHF), neurodegenerative diseases, liver failure, kidney failure, and diabetes. ERCs have been cleared by the FDA to begin studies in the United States.

ERCs have several distinguishing advantages to other stem cell therapies: a) Non-invasive method of collection; b) Unlimited supply of cells; isolated from menstrual blood of young healthy donors; c) Economical and scalable to manufacture; d) Exert higher therapeutic activity compared to other stem cells; and e) demonstrated safe in animal and pilot human studies.

Cautionary Statement
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

Add to Digg Bookmark with Add to Newsvine

Thomas Ichim, Ph.D
President and Chief Scientific Officer
Medistem Inc.
9255 Towne Centre Drive
Suite 450
San Diego, CA 92122
858 349 3617
twitter: @thomasichim

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Web 2.0 Latest News
None of us like slow mobile applications or those that ask us stupid questions. Our time has value. Google reports 82% of smartphone owners research and compare prices in stores, and we don’t want to be standing in the aisle answering questions the mobile app and vendor should already ...
I have three words for everyone in software testing: prioritize, prioritize, and prioritize. You can't test every possible permutation of your software, especially so with APIs and IoT devices where you're placing much of the user experience in the hands of integrators to your core pro...
DevOps Summit at Cloud Expo 2014 Silicon Valley was a terrific event for us. The Qubell booth was crowded on all three days. We ran demos every 30 minutes with folks lining up to get a seat and usually standing around. It was great to meet and talk to over 500 people! My keynote was we...
LittleBits Electronics offers the CloudBit Module which is a easy and quick option to create Internet connected devices. You can tag on Internet to many things without you needing to program anything. There are many, many projects that you can do with this module. Using IFTTT (read abo...
CodeBug is a cute, programmable and wearable device designed to introduce simple programming and electronic concepts to anyone, at any age. It is easy to program CodeBug using the online interface, which features colourful drag and drop blocks, an in-browser emulator and engaging commu...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)!

Advertise on this site! Contact advertising(at)! 201 802-3021

SYS-CON Featured Whitepapers